Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?
08:50am, Tuesday, 08'th Oct 2024
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
08:16am, Tuesday, 08'th Oct 2024
The healthcare sector is usually regarded as one of the safest and most stable spaces in the market, which becomes especially important and attractive during volatile periods such as today in the S&P
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
10:05am, Monday, 07'th Oct 2024
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health Set to Join S&P SmallCap 600
06:05pm, Friday, 04'th Oct 2024
NEW YORK , Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, Oc
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
02:21pm, Friday, 04'th Oct 2024
Thursday, The FDA determined the shortage of Eli Lilly And Co's LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over
08:51am, Friday, 04'th Oct 2024
Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly's obesity and diabetes drugs are no longer facin
Massive News for Hims & Hers Stock: The Truth About Today's Move
06:00am, Friday, 04'th Oct 2024
Hims & Hers may not be hurt by GLP-1 news the way investors think.
2 Winning Growth Stocks That Are Screaming Buys Right Now
05:15am, Friday, 04'th Oct 2024
These top stocks are on a winning streak and have the businesses to keep it going.
Market Today: Oil Prices Surge Amid Middle East Tensions, Hims & Hers Dips
05:32pm, Thursday, 03'rd Oct 2024
The S&P 500 closed just below 5,700, dropping nearly ten points or 0.2% from the previous day. Meanwhile, the Nasdaq Composite remained relatively flat, the Dow Jones Industrial Average fell by 0.4%,
3-Stock Lunch: Nvidia, Levi Strauss & Co & Hims & Hers Health Inc
03:42pm, Thursday, 03'rd Oct 2024
Quint Tatro, Joule FInancial president, joins 'Power Lunch' to discuss stock plays for three stocks.
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
02:10pm, Thursday, 03'rd Oct 2024
Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly's (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its list
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
06:49am, Thursday, 03'rd Oct 2024
Hims & Hers stock is undervalued at 25x forward free cash flow, presenting a tremendous bargain given its strong fundamentals and growth potential. Despite volatility and marketing spend concerns, Him
Is the soaring Hims & Hers stock a good investment?
05:24am, Thursday, 03'rd Oct 2024
Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in the last 12 months and by 112% this year, outperforming the benchmark Nasdaq
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
04:55am, Wednesday, 02'nd Oct 2024
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
10:05am, Wednesday, 25'th Sep 2024
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
